Drug Trial Radar · NCT05945732
DESTINY Breast Respond HER2-(Ultra)Low Europe
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,295
Planned (sponsor's estimate)
Start
Oct 24, 2023
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jul 14, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.
Conditions
- Unresectable Breast Cancer
- Metastatic Breast Cancer
- HER2-low Expressing Breast Cancer
- HER2-(Ultra)Low Expressing Breast Cancer
Interventions
Trastuzumab deruxtecanDrug
This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice. Trastuzumab (T-DXd) to be administered according to the SmPC. Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Real World Time to Next Treatment (rwTTNT1) in Participants With Unresectable and/or Metastatic Breast CancerTime frame: Baseline up to approximately 37 months
Locations
216 sites in 10 countries. Site status is shown where the registry gives one.
Medizinische Universität Graz
Graz, Austria · Terminated
Medizinische Universität Graz
Graz, Austria · Recruiting
Medizinische Universität Innsbruck
Innsbruck, Austria · Recruiting
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria · Recruiting
LKH Hochsteiermark-Leoben
Leoben, Austria · Withdrawn
Ordensklinikum Linz GmbH Barmherzige Schwestern
Linz, Austria · Recruiting
Interne II, LKH Feldkirch
Rankweil, Austria · Active not recruiting
KH der Barmherzigen Brüder Salzburg
Salzburg, Austria · Recruiting
Uniklinikum Salzburg
Salzburg, Austria · Recruiting
Medical University of Vienna
Vienna, Austria · Recruiting
Medizinische Universität Wien
Vienna, Austria · Terminated
Krankenhaus Hietzing
Vienna, Austria · Recruiting
Salzkammergut Klinikum Vöcklabruck
Vöcklabruck, Austria · Recruiting
Klinikum Wels-Grieskirchen GmbH
Wels, Austria · Active not recruiting
Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria · Recruiting
ASZ Aalst
Aalst, Belgium · Active not recruiting
Chirec Delta Hospital
Auderghem, Belgium · Active not recruiting
Imeldaziekenhuis Bonheiden
Bonheiden, Belgium · Active not recruiting
AZ Klina
Brasschaat, Belgium · Active not recruiting
AZ Sint-Jan Brugge av
Bruges, Belgium · Active not recruiting
CHU Brugmann
Brussels, Belgium · Active not recruiting
Cliniques universitaires Saint-Luc
Brussels, Belgium · Active not recruiting
Chu Helora- Hôpital de La Louvière- site Jolimont
Haine-Saint-Paul, Belgium · Active not recruiting
Jessa Ziekenhuis
Hasselt, Belgium · Active not recruiting
CHU Tivoli
La Louvière, Belgium · Active not recruiting
CHC MontLegia
Liège, Belgium · Active not recruiting
Hôpital de la Citadelle
Liège, Belgium · Active not recruiting
CHU UCL Namur/Site Sainte Elisabeth
Namur, Belgium · Active not recruiting
Clinique Saint Pierre Ottignies
Ottignies, Belgium · Active not recruiting
VITAZ
Sint-Niklaas, Belgium · Active not recruiting
CHR Verviers East Belgium
Verviers, Belgium · Active not recruiting
Aalborg Universitetshospital, Syd
Aalborg, Denmark · Terminated
Aarhus University Hospital
Aarhus N, Denmark · Active not recruiting
Herlev Hospital
Herlev, Denmark · Active not recruiting
Onkologisk og Palliativ afdeling, Nordsjællands Hospital
Hillerød, Denmark · Active not recruiting
Naestved Hospital
Næstved, Denmark · Active not recruiting
Sygehus Sønderjylland, Sønderborg
Sønderborg, Denmark · Terminated
CHU Amiens Picardie
Amiens, France · Active not recruiting
Clinique de l'Europe
Amiens, France · Active not recruiting
Hôpital Privé d'Antony
Antony, France · Withdrawn
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.